<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05013242</url>
  </required_header>
  <id_info>
    <org_study_id>MS.19.09.791.R1</org_study_id>
    <nct_id>NCT05013242</nct_id>
  </id_info>
  <brief_title>Goserline Acetate VS Dienogest in Endometriosi</brief_title>
  <official_title>Goserline Acetate Versus Dienogest in Treatment of Pain Associated With Endometriosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      clinical trial aims to evaluate efficacy of dienogest (DNG) in comparison to goserline&#xD;
      acetate in complete 12 week treatment of pain in women suffer from chronic pelvic pain&#xD;
      diagnosed as endometriosis by laparoscopy and histopathology.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a clinical trial study of 12-week trial of GnRH (zoladex 3.75mg) injection&#xD;
      once every 4 weeks and Visanne (dienogest 2mg) oral once daily for 12 weeks in patients&#xD;
      confirmed endometriosis by laparoscopic surgery.&#xD;
&#xD;
      Pretreatment assessment, the patients will be questioned about their pelvic symptoms&#xD;
      (dysmenorrhea, nonmenstrual pelvic pain, and deep dyspareunia) after taking full history and&#xD;
      examination , The study will investigate and evaluate possible early, long side effects and&#xD;
      efficacy of treatment to controlling the pain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 25, 2020</start_date>
  <completion_date type="Anticipated">December 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 25, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients with pain symptoms reduction</measure>
    <time_frame>12 week</time_frame>
    <description>number of patients with endometriosis-associated pain symptoms reduction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>assessment change in pain severity</measure>
    <time_frame>12 weeks</time_frame>
    <description>pain severity assessment after treatment by visual analogue scale as determined by measuring the distance (mm) on the 10-cm line between the &quot;no pain&quot; anchor and the patient's mark providing a range of scores from 0-100</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>group use GnRH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GnRH (zoladex 3.75mg) injection once every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group use Visanne (dienogest 2mg) oral once daily for 12 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Visanne (dienogest 2mg) oral once daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoladex</intervention_name>
    <description>evaluate efficacy of Zoladex in complete 12 week treatment of pain in women suffer from chronic pelvic pain diagnosed as endometriosis</description>
    <arm_group_label>group use GnRH</arm_group_label>
    <other_name>Gnrh</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Visanne</intervention_name>
    <description>valuate efficacy of Dienogest in complete 12 week treatment of pain in women suffer from chronic pelvic pain diagnosed as endometriosis</description>
    <arm_group_label>Group use Visanne (dienogest 2mg) oral once daily for 12 weeks</arm_group_label>
    <other_name>Dienogest</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non pregnant women confirmed to have endometriosis by histopathology and not received&#xD;
             any hormonal treatment yet. Also, medical treatment was the proper choice for&#xD;
             treatment of each case.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women suspect pregnancy.&#xD;
&#xD;
          -  Breast feeding women.&#xD;
&#xD;
          -  Previous use of hormonal agents (progestin less than 6 months, danazol less than 3&#xD;
             month, oral contraceptive pills less than 1 month before screening).&#xD;
&#xD;
          -  Women with other gynecological pathology interfere with treatment we will use.&#xD;
&#xD;
          -  Using of corticosteroids.&#xD;
&#xD;
          -  Family history of osteoporosis.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alaa Mosbah</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura university faculity of medicine , obstetric and gyneclogy department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>safaa M ismael, resident</last_name>
    <phone>00201281857175</phone>
    <email>roses_lover_2007@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>alaa mosbah, prosfeesor</last_name>
    <email>alaamosbah@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mansoura University</name>
      <address>
        <city>Mansoura</city>
        <state>الدقهلية</state>
        <zip>35111</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Dienogest</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

